Kala is backed by leading life science investors.
CAM Capital™ was established in 2012 by Bruce Kovner following his retirement from Caxton Associates, the macro hedge fund he founded and managed from 1983 to 2011. CAM Capital manages assets exclusively for entities related to Mr. Kovner and its senior employees. For more information please visit www.camcapital.com.
Longitude Capital Management
Longitude Capital is a private investment firm that focuses on venture growth investments in drug development and medical technology. The firm builds balanced portfolios of mid-stage to commercial-stage companies with clinically de-risked assets that are likely to achieve key value-creating milestones within three-to-five years. Besides traditional venture capital investments, Longitude’s investment team also proactively searches for “special situations”, such as spin-outs, recapitalizations, PIPEs, royalties and structured transactions, across both privately-held and publicly-traded companies. For more information please visit www.longitudecapital.com.
Lux Capital Management
Lux Capital is a leading venture firm focused on founding, seed, and early stage investments in emerging technologies. Lux takes an active role in helping entrepreneurs build successful businesses in Energy, Life Sciences, and Technology. The Lux investment team has founded more than 20 companies from scratch, including Caliper, Genocea, Illumina, Kala, Kurion, Lux Research, Nanosys, Neurocrine Biosciences, and Vertex Pharmaceuticals. For more information please visit www.luxcapital.com.
From biopharmaceuticals to medical devices, diagnostics, and healthcare services, OrbiMed is scouting the globe for innovations that will help ensure humanity lives healthier, longer and more productive lives. We have been investing globally for over 20 years across the healthcare industry: from early-stage private companies to large multinational corporations. Our team of over 80 distinguished scientific, medical, investment and other professionals manage approximately $15 billion across public and private company investments worldwide. For more information please visit www.orbimed.com.
Polaris Partners invests in exceptional technology and healthcare companies across all stages of their lifecycles. With offices in Boston, San Francisco, and Dublin, we partner globally with an unparalleled network of repeat entrepreneurs, top scientists and emerging innovators who are making significant contributions in their fields and vastly improving the way in which we live and work. For more information please visit www.polarispartners.com.
RA Capital Management, LLC (“RA Capital”) is a crossover fund manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to lead private, IPO, and follow-on financings for its portfolio companies, both facilitating the crossover process and allowing management teams to drive value creation with minimal capital concerns from inception through commercialization. RA Capital’s scientifically trained research team is intensely data driven in its continual effort to identify early breakthroughs and originate conviction in new ideas. The team’s understanding of industry best practices is derived from an extensive collection of case studies documenting the impact of clinical trial design, partnership structures, public market dynamics, and many other factors on valuation and business viability. For more information please visit www.racap.com.
Third Rock Ventures
Third Rock Ventures is a leading healthcare venture firm focused on investing and launching companies that make a difference in people’s lives. The Third Rock team has a unique vision for ideating and building transformative healthcare companies. Working closely with our strategic partners and entrepreneurs, Third Rock has an extensive track record for managing the value creation path to deliver exceptional performance. For more information please visit www.thirdrockventures.com.
Founded in 1996, Vivo Capital is a healthcare investment firm focused on investing in and building high quality companies in the U.S. and China. With more than $1.7 billion under management, Vivo employs a unique multi-pronged strategy of identifying and working with companies with promising development stage and commercial stage therapeutic products in the U.S. and revenue stage companies in China. Vivo Capital has offices in Palo Alto, California, Shanghai, and Beijing, China. For more information please visit www.vivocapital.com.
Ysios Capital is a leading Spanish venture capital firm that provides private equity financing to early- and mid-stage human healthcare and life science companies. We target the entire healthcare and biotechnology industry, with a special focus on pharmaceuticals, diagnostics and medical devices. Founded in 2008, Ysios Capital has €130 million in assets under management distributed over two funds. The second fund has a target size of €100 million and will remain open to new investors until September 2016. For more information please visit www.ysioscapital.com.